Work

Ultrasound/Nanodroplet Enabled PCSK9 vaccine platform for atherosclerosis management

Year: 2026
Type: article
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) drives low-density lipoprotein receptor (LDLR) degradation, making its targeted inhibition a cornerstone of atherosclerosis management. Here, we develop an Ultrasound/Nanodroplet-Enabled PCSK9 (UNEP) vaccine platform for efficient PCSK9 blockade. To establish an immunocompetent microenvironment, an injectable hydrogel, co-loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF) and STING agonist-encapsulating extracellular vesicles (EVs), is utilized to recruit and activate dendritic cells (DCs), forming a hydrogel-based immune niche. Subsequent administration of PCSK9 antigen-loaded phase-transition nanodroplets (NDs) into this depot, coupled with targeted ultrasound irradiation, achieves spatiotemporal and efficiently delivery of the antigen. Consequently, the UNEP vaccine elicits robust and durable anti-PCSK9 immunity, sustaining high antigen-specific IgG titers for over four weeks. In ApoE −/− mice, this strategy effectively neutralized PCSK9, restored hepatic LDLR expression, and led to a significant reduction in aortic atherosclerotic plaque burden. By synergistically integrating hydrogel biomaterials, EV-based adjuvants, and ultrasound-responsive nanotechnology, this platform provides a highly versatile paradigm for precision vaccination.
Language: English
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W7226644367
FWCI:
Cites:
Cited by:
Related to: 10